Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1beta-based treatments for immune-mediated inflammatory diseases. Its lead asset, abdakibart (AVTX-009), is a humanised monoclonal antibody that binds interleukin-1beta with high affinity, and the company is developing it principally in hidradenitis suppurativa, where a Phase 2 trial read out positively and a Phase 3 programme is being planned. Avalo was incorporated in 2011 as Cerecor Inc. and renamed Avalo Therapeutics in August 2021, refocusing on immunology after divesting its earlier paediatric and rare-disease assets. The company raised approximately $375 million in a May 2026 underwritten public offering priced at $17.75 per share to fund the abdakibart programme, and it reports substantial cash relative to its operating spend. Avalo is headquartered in Wayne, Pennsylvania and trades on the Nasdaq under the ticker AVTX.